Home / Transcripts / AbCellera Biologics Inc. (ABCL) · May 11, 2026

AbCellera Biologics Inc. (ABCL) Earnings Call Transcript

May 11, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 44 min

Earnings Call Speaker Segments

Tryn Stimart executive
#1

Hello, and welcome, everyone. We appreciate you joining us for AbCellera's earnings call covering the first quarter of 2026. I'm Tryn Stimart, serving as AbCellera's Chief Legal and Compliance Officer. Joining us on today's call are Dr. Carl Hansen, our President and CEO; Dr. Sarah Noonberg, our Chief Medical Officer; and Andrew Booth, our Chief Financial Officer. During this call, we may share perspectives on our strategic priorities and financial outlook, reflecting our current expectations, consistent with the safe harbor protections established under the Private Securities Litigation Reform Act of 1995. Various risks, uncertainties, and other factors could impact the statements we make, resulting in actual outcomes that differ materially from what we describe. To get a fuller picture of these risks, you can look at the Risk Factors portion in our latest Form 10-K, along with the 10-Q documents we've since submitted to the SEC. AbCellera isn't committing to revise any forward-looking statements if things change or new situations come up after today. You can find our presentation, the earnings press release, and our SEC filings over on our Investor Relations site. Everything we share regarding our pipeline is meant for the investment community rather than as promotion. Before we get into our prepared remarks, just a reminder that this call is being recorded and a replay will be posted on our Investor Relations website, and that whenever we mention dollars on this call, we mean U.S. dollars. Once our prepared comments are done, we'll take your questions. I'll now hand things over to Carl.

Carl Hansen executive
#2

Thanks, Tryn, and I appreciate all of you being here with us today. For AbCellera, 2026 could prove to be a significant year; we entered it financially strong, with our platform and major infrastructure efforts essentially finished, and with our internal pipeline positioned for a number of catalysts across the coming 24 months. Delivering top line data readouts for ABCL635 and ABCL575, moving ABCL688 and ABCL386 through IND-enabling work, and bringing at least 1 additional development candidate into our pipeline rank among our main priorities for the year. In January, supported by early biomarker and safety data, we said that ABCL635, our lead program, had entered Phase II testing. Without question, the single most significant data readout of 2026 will be this study's top line results, which we expect in Q3. During today's call, we're pleased to share interim Phase I data for this program. As a reminder, ABCL635 is a potent NK3R antagonist — NK3R being a GPCR target clinically validated for treating vasomotor symptoms, commonly called hot flashes; it is the first antibody targeting a GPCR from our platform to reach clinical testing, and we are developing it as a possible first-in-class antibody medicine for nonhormonal treatment of moderate to severe hot flashes tied to menopause. Our view is that ABCL635 could address a substantial need and market opportunity within women's health. For the majority of women, hot flashes rank as the most troublesome menopause symptoms. They may be extremely disruptive to sleep, work, and family life, and they represent a meaningful burden lasting a median of more than 4 years. At any moment, an estimated over 12 million women across the U.S. are living with moderate to severe VMS, and more than 6 million of them will pursue treatment. Menopause hormone therapy — effective and currently the standard of care — is inappropriate for at least an estimated 20% of these women owing to contraindications, tolerability, and other considerations. Consequently, we believe more than 1 million women in the U.S. could benefit from safe and effective nonhormonal options. Assuming merely price parity with approved small molecule NK3R antagonists, we put the total addressable U.S. market for non-hormonal VMS treatments at no less than $6 billion each year. Beyond that, we see upside potential both in pricing and in broader use among patients whose VMS stems from cancer treatments that lower hormone levels. That includes patient populations with breast, ovarian, and prostate cancers. ABCL635 is intended to offer a treatment option with efficacy comparable to small molecules, a differentiated safety profile that avoids the need for liver enzyme monitoring, and a dosing convenience advantage via once-monthly subcutaneous self-injection. I'll now hand things to Sarah to walk through program details and our interim Phase I results. Sarah?

Sarah Noonberg executive
#3

Thanks, Carl. I want to walk through the Phase I results that supported our decision to move ABCL635 forward into Phase II development. This first-in-human Phase I study had a randomized, double-blind, placebo-controlled design with 2 parts, and its purpose was assessing safety along with pharmacokinetics and pharmacodynamics among healthy volunteers. Part A looked at single ascending doses of either ABCL635 or placebo in 40 healthy men and postmenopausal women, who were split across 5 cohorts. Within each cohort there were 8 participants — 6 assigned to ABCL635 and 2 assigned to placebo — and men and women were both represented in every cohort. A single subcutaneous dose of the study drugs, spanning 30 milligrams to 900 milligrams, was given to participants, who were then followed for roughly 20 weeks. Today we have unblinded findings from that single ascending dose portion and will go over them; Part B examined multiple ascending doses of ABCL635 or placebo in 16 postmenopausal women. Those participants were dosed at 300 milligrams or 600 milligrams once a month over 3 months, with 20 weeks of follow-up beginning after the last dose. Findings from the multiple ascending dose cohorts remain blinded because the final follow-up visits haven't finished yet. Key demographic features of the single ascending dose study population appear on this slide. Among the 40 healthy participants, 30 sat within the total ABCL635 group across 5 escalating dose cohorts, while 10 made up the pooled placebo group. Enrollment focused on healthy adults aged 40 to 65, with a median age in the mid-50s for both treatment and placebo groups; both men and postmenopausal women took part. Although women made up a larger share of the total ABCL635 population while men made up a larger share of the pooled placebo group, note that each individual cohort had at least 2 male participants receiving ABCL635, which matters when assessing pharmacodynamic endpoints. Across all cohorts, the overwhelming majority of participants were Caucasian. Baseline body mass index, or BMI, was similar in most groups, except for the 900-milligram group, where median weight was lower and BMI was correspondingly lower. In our view, that difference did not meaningfully affect the study's overall conclusion. On the safety side, ABCL635 was generally well tolerated in every cohort. As of today, no serious adverse events, severe adverse events, or adverse events resulting in discontinuation have been reported. Also worth highlighting, we saw no adverse events involving liver toxicity, a key differentiator for this program. Any adverse event occurred at an overall incidence of 50% in the total ABCL635 treatment group and likewise in the pooled placebo group, and grade 1 accounted for the vast majority of reported adverse events. Every adverse event reported in at least 2 participants during the study period, irrespective of relationship to study drug, is shown in the table. What we found as a possible signal was only headache that resolved on its own, and those cases were concentrated in the group receiving 900 milligrams. These events tended to be mild, usually appeared during the first 1 to 2 days after dosing, and cleared with no complications. It is worth noting that no headache adverse events at all were reported among those given 600 milligrams. Events related to the injection site were uncommon in both treatment arms, and gastrointestinal symptoms, diarrhea among them, arose at low rates, with no obvious relationship to dose and no rise compared with placebo. Furthermore, a blinded review of safety data from the multiple ascending dose portion, which is still ongoing, points to no additional safety signals. Just as in the single ascending dose portion, no serious adverse events, severe adverse events, adverse events causing discontinuation, or liver-related adverse events have been reported to date. Let's take a closer look at liver safety. This slide shows liver function laboratory tests over time after treatment with escalating doses of ABCL635 in the single ascending dose portion. On the whole, mean AST, ALT, and bilirubin values stayed stable after ABCL635 was given, with nothing suggesting a dose-dependent pattern. The dotted lines on each graph indicate the mean upper limit of normal, so these numbers are quite reassuring, as are our blinded reviews of liver function tests from the multiple ascending dose portion. Turning to pharmacokinetic data, ABCL635 showed favorable linear pharmacokinetics across doses, with low variability overall. As the left panel shows, systemic exposure to ABCL635 is roughly dose proportional, which gives a predictable profile for choosing doses in future studies. The estimated half-life of 635 is about 24 days, which we believe supports a monthly dosing schedule. The right panel presents data from the multiple ascending dose portion, where 300 milligrams was given every 4 weeks. This profile confirms that ABCL635 behaves consistently when doses are repeated, and analysis of our 600-milligram repeat dose cohort is ongoing right now. Although immunogenicity assays have not been run yet, the overall PK profile and the general consistency in observed clearing rates are reassuring. Before we move into Phase I data on pharmacokinetics, it is worth reviewing the biology of NK3R, especially in the KNDy neurons located in the hypothalamus. Besides being centrally involved in the physiology of VMS, KNDy neurons are centrally involved in regulating sex hormones through their effect on pulsatile GnRH secretion. GnRH then acts on the pituitary to release FSH and LH, which in turn stimulate estrogen and testosterone release from gonadal tissues. Neurokinin B binding to the NK3 receptor mediates these KNDy neuron functions. So the ability to block NKB/NK3 receptor signaling can be measured by evaluating the downstream effects of blocking GnRH release, namely circulating levels of estrogen or testosterone. While measuring testosterone levels in postmenopausal women is challenging because levels are low and vary within and between individuals, measuring testosterone levels in men offers a more stable surrogate marker for evaluating NK3R target engagement of KNDy neurons. In men, testosterone levels had already been established as a biomarker for NK3R target engagement during the early development of fezolinetant, an oral small molecule, within Phase I studies. The figure to the right, which was adapted from the 2016 paper, displays testosterone suppression that is dose-dependent after a single dose of fezolinetant, given at amounts from 12 milligrams up to 180 milligrams. This information offers a helpful reference point for NK3R target engagement, and together with later Phase II trials, it lets us assess how doses linked to varying levels of NK3R target engagement have converted into efficacy for VMS outcomes. Thus, enrolling men in our single ascending dose trial mattered because it allowed us to tackle a central scientific question: can an antibody reach NK3R in the hypothalamus and produce a similar impact on suppressing serum testosterone? Notably, we began the study believing that the hypothalamic region where KNDy neurons are mainly found—the infundibular nucleus—was not entirely shielded by the usual blood-brain barrier, which aligns with how KNDy neurons work in detecting hormone levels from systemic circulation. We had observed encouraging results in nonhuman primates indicating these neurons could be reached by an antibody, yet it remained crucial to reduce this scientific risk early in clinical trials.

Sarah Noonberg executive
#4

So with that context, what you see on this slide is testosterone information across time—single doses of ABCL635 on the left side, and on the right, data adapted from the published fezolinetant study. Both figures show results transformed into the placebo-adjusted percent change in testosterone relative to baseline. That transformation matters especially for the fezolinetant results, because testosterone naturally fluctuates over the course of a day, across a 24-hour period. Looking at the left panel, one dose of ABCL635 produced sustained, dose-dependent suppression of testosterone in men across a 4-week span, with eventual return to baseline somewhere between 8 and 12 weeks. In contrast, a single fezolinetant dose gave transient, dose-dependent testosterone suppression lasting hours, with baseline restored inside 24 hours. Worth noting: the approved 45-milligram fezolinetant dose was tied to a transient testosterone drop reaching a maximum of 50% of baseline values across several hours. On the other hand, ABCL635 at 300, 600, and 900 milligrams produced sustained testosterone reductions ranging from 50% to more than 75% lasting several weeks. Matching these NK3R antagonism findings for control of the hypothalamic pituitary gonadal axis of testosterone, ABCL635 showed dose-dependent suppression of the pituitary hormones FSH and LH, with clear effects at 300, 600, and 900 milligrams. Based on what we've seen in the pharmacodynamic results, our confidence is high that ABCL635 is able to get to the KNDy neurons located within the infundibular nucleus, and that means a major scientific hurdle for this program has now been cleared. Wrapping up, then: in the unblinded interim findings from the single ascending dose cohort, ABCL635 demonstrated a tolerability profile that looks favorable, pharmacokinetics that would allow for subcutaneous administration once a month, and target engagement that is both strong and sustained—matching or going beyond the levels that were previously reported in the literature for fezolinetant, the approved small molecule. Armed with that information, we acted swiftly and launched Phase II studies in January of this year. For the trial, we went with a single 600-milligram dose administered subcutaneously. Our reasoning is that this comes closest to mimicking the exposure you'd see from 300 milligrams dosed at steady state, and it might serve as a workable loading dose when starting treatment, potentially giving us the strongest early impact on VMS. Right now, what we're focused on is running the Phase II part of the trial, where we'll measure how well ABCL635 reduces both how often VMS occurs and how severe it gets — the very same endpoints we anticipate relying on later in late-stage development. This is a multicenter, randomized, double-blind, placebo-controlled trial enrolling roughly 80 patients who have moderate to severe VMS. For the eligibility requirements overall, we aimed to make them similar to the criteria that have been published for the approved small molecules when they went through Phase III testing. In this trial, participants are assigned by chance in a 1:1 ratio to get either one dose of ABCL635 at 600 milligrams or a placebo that matches it. The main measure of efficacy comes at 4 weeks, though patients continue to be tracked for another 8 weeks so that researchers can look at how drug concentrations relate to efficacy and help construct a PK/PD model. After the initial 12-week placebo-controlled treatment phase concludes, all participants are given the option to enter an open-label extension, where the dose administered would be 600 milligrams. The study is enrolling well, and as of now we anticipate releasing top line efficacy and safety data in Q3 of this year. Once that news is out, we intend to present additional findings at upcoming medical meetings. From our standpoint, a successful Phase II stage of this trial would remove a great deal of risk from the program. With that in mind, we've already begun preparing what comes next, which would include a late-stage clinical development effort for ABCL635 in moderate to severe VMS linked to menopause, along with additional research exploring whether ABCL635 might ease VMS connected to breast cancer and prostate cancer therapies that are frequently prescribed. At this point I'll turn it over to Carl, who will cover the key points across our wider pipeline and the upcoming catalysts.

Carl Hansen executive
#5

Thanks, Sarah. It goes without saying that we're extremely happy with what we've seen in the Phase I data for ABCL635, and we're eager to see top line results from the Phase II study that's currently underway, which is still expected in Q3. Now, on to the wider portfolio. We anticipate the top line Phase I readout for ABCL575, our second clinical program, during Q4 of this year. As we've said before, ABCL575 is an OX40 ligand antagonist with potential to be best-in-class. From the beginning, our approach has been to only finish Phase I studies before we partner it. Right now, we have no plans to take it beyond Phase I. In addition to ABCL635 and ABCL575, we remain on track to have as many as 3 more clinical stage programs by the close of 2027. That figure includes our 2 undisclosed programs, ABCL688 and ABCL386, and we believe both represent compelling opportunities in large markets. We anticipate that both will begin clinical development in Phase I/II studies, with a clear path toward achieving early proof of concept in patients. We'll share more details about these programs once they enter clinical studies. And last, we're working toward choosing our fifth development candidate during the first half of this year. There's still work left to do, but we're on track to meet this goal. With that, I'll pass things to Andrew for our financials. Andrew?

Andrew Booth executive
#6

Thank you, Carl. As Carl noted, AbCellera remains in a solid position when it comes to liquidity, holding about $530 million in cash and equivalents, plus roughly $125 million in committed government funding that's available to us as we carry out our strategy. Our plans continue to move forward, centered on internal programs and on making the most of what we've invested in process development and clinical manufacturing. Now to revenue and expenses. For the quarter, revenue came in at around $8 million, versus total revenue of approximately $4 million during the same quarter of 2025, with research fees making up most of it in both periods. Regarding research fee revenue, as we've said before, we anticipate it will generally decline as our attention shifts to the internal pipeline. R&D expenses for the quarter totaled approximately $47 million, roughly $4 million above last year, and that spending mirrors where we're directing investment in our internal programs; SG&A expenses came to approximately $12 million, compared with roughly $19 million a year ago. That decrease of more than 35% in SG&A is tied to the wrapping up of our intellectual property litigation and to team changes that followed from focusing on our internal pipeline. On earnings, we're reporting a net loss of roughly $43 million for the first quarter of 2026, against a loss of about $46 million during the same period a year earlier. On a per-share basis, that comes to a loss of $0.14, basic and diluted. Now to cash. Operating activities during the first quarter absorbed approximately $34 million in cash and equivalents. Leaving aside marketable securities and all other investment activities, the figure was just $3 million for the quarter. That aligns with the near completion of our sizable investments in facilities and manufacturing capabilities, which wrapped up in 2025. Under our treasury strategy, $428 million sits in short-term marketable securities, and our investment activities for the quarter included putting $23 million into those holdings. All told, we ended the quarter with $531 million in cash, cash equivalents and marketable securities, which is a $30 million decline in the cash — in cash for the first quarter of 2026. As a reminder, we've secured funding commitments to advance our internal pipeline from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia; that available capital isn't reflected on our balance sheet. And with more than $530 million in cash and equivalents, together with the untapped portion of our secured government funding, we have approximately $655 million in available liquidity to keep executing our strategy. Beyond that, we hold additional available liquidity through our ownership of another Vancouver lab-based lab and office building, along with our GMP facility. When it comes to company expenditures overall, our capital needs are quite manageable. Our view remains that our liquidity is enough to cover pipeline investments for a minimum of the coming three years. With that said, we're ready to take your questions. Operator?

Stephen Willey analyst
#7

I'm just wondering — when you consider how much testosterone suppression you can get with the 300 mg and 600 mg doses. You mentioned that a loading dose approach might be something worth trying. But what I'd like to know is, now that you've observed the testosterone suppression, and given what you understand about testosterone as a pharmacodynamic marker based on what we've seen with certain small molecule antagonists, do you believe those drugs are leaving efficacy on the table? And could a case for improved efficacy potentially show up in the 4-week VMS severity and frequency data?

Carl Hansen executive
#8

Excellent question, Steve. This is Carl; first off, I'd like to emphasize that this trial is primarily aimed at assessing target engagement on NK3R within the infundibular nucleus. So in our view, the biomarker result speaks to that directly, though it doesn't directly tell us about efficacy. So guessing what the final efficacy will be — it's hard to hold back from that, but that's the very reason we're conducting the Phase II study and what we'll find out in Q3. Beyond that, our position, our base TPP and our commercial evaluation, is that a truly winning product — and potentially a blockbuster — would be one with efficacy that matches or equals the small molecules, a cleaner safety profile with no liver monitoring, and a more convenient once-monthly subcutaneous injection; from that angle, that's the standard. If we observe that, or something that — that backs it up in Q3, we'll be celebrating. We do believe there's a solid scientific rationale, grounded in the target engagement we've observed, that we could perform better, but there's still science left to be worked through. And I don't want to get ahead of that, because that's exactly why we're running the study that reads out in Q3.

Stephen Willey analyst
#9

Okay, got it. Then perhaps a brief additional question. When you consider what the upcoming step in development for 635 could look like, I realize you describe this as being in "late-stage" development; however, do you believe enough dose optimization effort will have been completed that you could possibly proceed straight into a Phase III trial during 2027?

Sarah Noonberg executive
#10

Stephen, Sarah here. My view is that we're going to examine that proof-of-concept Phase II readout. And one reason we're tracking subjects across 12 weeks is so we can truly construct a strong PK/PD model, examining efficacy as time passes while drug concentrations keep declining. That should provide us with a solid understanding of the way those drug concentrations connect to efficacy. We think that once we have such data available, along with a clearly validated mechanism of action, we'll be in an excellent position to approach regulators regarding the late-stage development programs. It's possible regulators could ask us to evaluate one more dose in Phase III, and I don't believe we'd be entirely opposed to that, even though I question whether we'll actually need to given the data we'll have, yet that's going to be a conversation with regulators.

Evan Seigerman analyst
#11

I have two things. First, the testosterone results you provided are clearly quite compelling. Could you help us understand what that might mean in terms of benefit for patients who have VMS, and you brought up possibly broadening indications past VMS into — from VMS into oncology. What's the right way for us to consider that possible opportunity?

Carl Hansen executive
#12

Thank you, Kevin. My apologies, Evan — this is Carl speaking. I'll take the first question, then pass things over to Sarah. What you're asking overlaps with what Steve raised; if you review the clinical development data that's been published on fezolinetant, there's fairly solid information supporting a link between target engagement — measured through suppression of testosterone levels — and efficacy. That's data we have been examining. It's among the reasons we see a strong argument that greater target engagement yields improved efficacy. One caveat there is that those experiments involve small molecules. Consequently, the correlation observed with small molecules might or might not carry over to an antibody. That's especially true given that NK3R is expressed in a different region of the brain that matters. That region is the preoptic nucleus, and we lack a direct read on target engagement there. So although we're quite encouraged and believe we are hitting NK3R on the key neurons — the KNDy neurons — scientific risk remains to be crossed. And that's — as I told Steve, that's the reason we're conducting the Phase II. Should those data arrive in the manner we hope, then in my view the program becomes highly derisked, and we'd move rapidly toward further development; and I believe that's the second portion of your question, which I'll now hand to Sarah.

Sarah Noonberg executive
#13

Thus, looking ahead, besides advancing into late-stage development for VMS tied to menopause, we also see substantial potential and patient value in addressing induced menopause linked to different cancer therapies. For breast cancer, that would involve treatment using tamoxifen, aromatase inhibitors, or oopherectomy, producing a chemically or surgically induced menopausal state that can lead to especially severe VMS symptoms. In prostate cancer, androgen deprivation therapy along with androgen receptor antagonists and other treatments that lower hormonal levels likewise produce the same hot flash symptoms. Therefore, we believe — and the oral small molecules have started to assess this further too — that patients can benefit beyond what is seen with naturally occurring menopause.

Srikripa Devarakonda analyst
#14

Nice work on the data. I have a few questions. First, regarding the Phase II dose of 600 mg given once — you said it was chosen since it comes close to the anticipated Cmax at steady state for the 300 mg regimen. Please walk us through how that choice was made. Even more important, could there be a chance that a single 600 milligram dose won't hold the testosterone suppression floor through to the end of the 4-week window in the Phase II trial? Is that a concern? Second, the 600 mg dose appears to have a reduced AE rate. Is that just a matter of small cohorts, so we shouldn't read too much into it? Or might it be — based on what you've observed with the 900-milligram and 300-milligram groups — that this is genuinely some kind of sweet spot for tolerability?

Sarah Noonberg executive
#15

Thanks, Kripa, I appreciate that question. Regarding durability of effects across 4 weeks, we have our PK data demonstrating a 24-day half-life, plus PD data demonstrating sustained target engagement and testosterone suppression. We do believe 4 weeks will be a solid time period to evaluate efficacy. Of course, the results from that Phase II study will give us a conclusive answer, since we're measuring VMS each week across the 12-week period. So that question will be answered. As for the AE rate you brought up, my expectation is that it's small numbers. At 600, we didn't see much in the way of safety findings, though with the 900-milligram cohort, it's difficult to tell whether this is a real finding. Those headache events happened on day 1 and day 2, which really isn't when exposures are at their maximum, and frequently in a Phase I setting, these are people who haven't necessarily slept well in a dormitory-like environment, and they can't have coffee in the morning. So headache is frequently a common adverse event across various cohorts in studies. It's also worth noting that the placebo patient with headache was also a 900-milligram patient. So it could be that this is a real safety signal; it could also be that it's just small numbers. But clearly, our safety at 600 milligrams is very reassuring.

Carl Hansen executive
#16

Let me also chime in here — I simply wanted to tack on that, when you examine the biomarker results, the testosterone, along with the LH and the FSH, every one of them indicates that with the 600-milligram dose, we achieve strong suppression throughout the entire dosing window. That is roughly the dose we'd anticipate at steady state from the 300. And 300 also happens to be one that fits readily with an auto-injector you can buy commercially at 2 milliliters. So when you put all of that together, it played into the choice to advance the 600.

Allison Bratzel analyst
#17

Perhaps I'll just ask something that builds on a few of the questions from before. Could you explain why the multiple ascending dose trial was capped at 600 mg? Did that stem from a ceiling effect related to target engagement, from the headaches that were observed, or from something else entirely? Then, regarding the multiple ascending dose data, my understanding is that you said it's still blinded. Could you make clear whether any of those results ought to be expected prior to the Phase II efficacy readout in Q3, or whether they'll come at the same time? Or simply, where does that stand right now?

Sarah Noonberg executive
#18

Yes. Allison, thank you for asking. Regarding the 600 milligram dose as the highest cohort in the MAD portion, our choice was driven mostly by the fact that it begins to get close to very high exposures well past what we believed would be necessary, or even commercially viable, to advance into late-stage development. The purpose is genuinely to give a safety window at exposures we consider suitable to move forward, and not due to any safety signals. No dose-limiting toxicity was observed anywhere in the study; and as for your second question, about the — could you say your second question again?

Allison Bratzel analyst
#19

Yes, that was just about whether data will come out from the multiple ascending dose part of the Phase I.

Sarah Noonberg executive
#20

That isn't something we anticipate disclosing. That said, as I mentioned, blinded safety data is something we're able to review, and really all that remains are the final safety follow-up visits. So we don't anticipate much shifting, though since those visits are still underway, unblinding hasn't happened. But no, our expectation is not to unblind that ahead of the Phase II readout.

Brendan Smith analyst
#21

I suppose I just want to nail down this discussion so I'm certain about what we're aiming for, biologically speaking. Because when I look at those testosterone curves, say on Slide 12, you're still seeing a reduction well above 50% at 4 weeks with the 600 mg dose. So would it be accurate to say that, in the end, the aim is to bring testosterone down and then hold it at that reduced level in a steady state? And the thinking being that you wouldn't want to stretch the dosing interval out even further, potentially, just to guarantee it remains suppressed? Or is there genuinely some optionality going forward regarding whether that's 5, 6-plus weeks? Just give us a sense of the over under there.

Sarah Noonberg executive
#22

Yes. I'd say the aim is stable, sustained target engagement throughout the dosing period. Based on the PK, we think that a dosing period of every 4 weeks is appropriate. However, since we're tracking patients for another 12 weeks, or a full 12 weeks, following treatment, we'll find out whether efficacy holds past that 4-week window, which would cause us to reconsider our dosing regimen. But right now, with the sustained target engagement at 600 and what we believe would be tied to 300 at steady state, we consider that sufficient for monthly dosing. Though clearly, the Phase II data will give us a bit more clarity.

Brendan Smith analyst
#23

All right, understood. And if I may, a quick follow-up regarding the 2 preclinical assets, 688 and 386 — my understanding is that IND-enabling studies remain ongoing at this point, but could you share whether you have any sense of one reaching clinical starts ahead of the other next year? Or would they be roughly on the same timeline for '27?

Carl Hansen executive
#24

This is Carl. Both are moving forward nicely. At this stage, I'd say we aren't ready to declare which of the two will get to the clinic first, though we'll provide an update on that as matters develop.

Debanjana Chatterjee analyst
#25

Congratulations on the data. I realize the MAD part is still blinded, so you're not able to go into detail. But given that these are postmenopausal women, some with VMS and some without, I'm wondering whether you've been gathering any type of PRO data from these women, in either the SAD or the MAD. And could you comment on any beneficial trends you're observing when it comes to VMS symptoms?

Sarah Noonberg executive
#26

While the women we're treating are postmenopausal and a number of them do experience VMS, we aren't collecting efficacy data during the multiple ascending dose portion. Our eligibility criteria differ, and we definitely aren't using the diaries — those have been reserved for Phase II, and from that Phase II in Q3 we anticipate a very robust answer.

Debanjana Chatterjee analyst
#27

I also have one more follow-up. In the MAD data that you provided for the 300-milligram dose given every 4 weeks, it's possible to observe a certain accumulation effect of the drug as time goes on. So with 600 mg, when we consider chronic dosing, what sort of PD impact do you anticipate? Also, do you believe there's still room for greater PD engagement? And does this carry any consequences for the risk-benefit ratio when we consider chronic dosing?

Sarah Noonberg executive
#28

What I'd say is that 600, 300, and 900 all demonstrate quite robust target engagement. Given that only a small number of participants were tested, it's genuinely difficult to claim that additional target engagement is something we're likely to observe. When we make a comparison, especially across the span of many weeks, against 45 milligrams of fezolinetant, we're quite confident that our level of target engagement—at least within the KNDy neurons, the infundibular nucleus—will prove adequate. We don't really think we'll need to go any higher. Obviously, with steady-state dosing, somewhat higher exposures will be achieved. That's another reason we're considering this loading dose approach, so that we can actually treat VMS rapidly, potentially within the first week to 2 weeks.

Carl Hansen executive
#29

Let me build on what was said. During the prepared remarks, Sarah noted that the antibody's half-life comes in at slightly below 1 month. Therefore, dosing once each month at 300 milligrams would produce buildup that begins to come close to the levels observed with the 600-milligram dose. And, exactly as Sarah stated a moment ago, you begin with 600 milligrams and afterward keep going at 300 milligrams once per month, which lets you reach peak efficacy immediately and then maintain a stable level all the way through the course of treatment.

Steve Seedhouse analyst
#30

I'd like to ask about — starting with the placebo arm in that VEOZAH testosterone comparator study, where there was a temporary dip in testosterone during the 24-hour follow-up. I believe you pointed out that this is clearly normal, the kind of diurnal fluctuation one would anticipate, so that's understandable. What I'm wondering is what you observed in the placebo arm of your SAD, and I simply wanted to verify whether it was essentially unchanged at steady state. Also, I'd like to confirm: given this dynamic, are you taking testosterone measurements at the same clock time daily for every assessment? Or does it get averaged across several measurements taken each day? I just want to verify that aspect of the protocol too.

Sarah Noonberg executive
#31

Certainly. Taking your second question first, yes, we attempt to draw testosterone at approximately the same time every day; since these participants come into the clinic rather than staying there, it isn't exact, but our goal is a morning testosterone draw at each visit, and I believe that's what we managed to do. Regarding the placebo arm, we didn't perform serial measurements across 24 hours the same way. However, with an antibody, with the sustained target engagement that we could observe, we saw no meaningful effects in the placebo group.

Steve Seedhouse analyst
#32

All right, and I'd like to inquire about how quickly this antibody starts working. Given that testosterone fell more or less across the initial 7 days following dosing, was that anticipated, first of all? Do you believe that reflects the bioavailability at the KNDy neurons located in the hypothalamus, or is it due to another cause? And regarding this target engagement kinetics that you're observing relative to VEOZAH, for which the nadir occurred roughly 8 hours after administration, what does that reveal regarding the pharmacology at play here?

Sarah Noonberg executive
#33

Yeah. What I'd point to as the primary distinction is simply how long it takes to achieve Cmax when you have a subcutaneously delivered antibody as opposed to an oral small molecule, in which case Cmax happens fairly fast. So absorption is going to require a bit of time, as will getting to the site of interest at its peak concentration. Honestly, I believe that's the sole distinction. From my perspective, the fezolinetant data demonstrates that the gap between PK and PD is extremely brief.

Carl Hansen executive
#34

Thank you all for being here on today's call. The progress has us enthusiastic, and we can't wait to bring you further updates down the road. Many thanks.

Operator operator
#35

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AbCellera Biologics Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AbCellera Biologics Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.